Seamless Therapeutics Launches with $12.5M Seed Financing to Advance Transformative Gene Editing Platform Based on Programmable Precision Designer Recombinases
Digital Health Global
MARCH 16, 2023
Seamless Therapeutics has a first-mover position with its innovative platform capable of modifying the long held standard recombination technology into a universal gene editing tool with unprecedented specificity. Forbion invests in life sciences companies that are active in the (bio) pharmaceutical space.
Let's personalize your content